Search Results - Miles, David W.
- Showing 1 - 4 results of 4
-
1
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally adv... by Miles, David W. (Author) , Gligorov, J. (Author) , André, F. (Author) , Cameron, D. (Author) , Schneeweiss, Andreas (Author) , Barrios, C. (Author) , Xu, B. (Author) , Wardley, A. (Author) , Kaen, D. (Author) , Andrade, L. (Author) , Semiglazov, V. (Author) , Reinisch, M. (Author) , Patel, S. (Author) , Patre, M. (Author) , Morales, L. (Author) , Patel, S. L. (Author) , Kaul, M. (Author) , Barata, T. (Author) , O’Shaughnessy, J. (Author) , Zhang, Q. (Author) , Shao, Z. (Author) , Wang, X. (Author) , Geng, C. (Author) , Yan, X. (Author) , Tong, Z. (Author) , Shen, K. (Author) , Yin, Y. (Author) , Sun, T. (Author) , Yang, J. (Author) , Feng, J. (Author) , Yan, M. (Author) , Wang, Y. (Author) , Liu, Q. (Author) , Zhang, S. (Author) , De Laurentiis, M. (Author) , Santoro, A. (Author) , Guarneri, V. (Author) , Colleoni, M. (Author) , Natoli, C. (Author) , Cortesi, L. (Author) , Placido, S. (Author) , Gianni, L. (Author) , Ferrau, F. (Author) , Livi, L. (Author) , Zambelli, A. (Author) , Del Mastro, L. (Author) , Tonini, G. (Author) , Montemurro, F. (Author) , Bianchi, G. (Author) , Pedersini, R. (Author) , Prete, S. (Author) , Allegrini, G. (Author) , Naso, G. (Author) , Vici, P. (Author) , Loirat, D. (Author) , Mailliez, A. (Author) , Priou, F. (Author) , Tredan, O. (Author) , Dalenc, F. (Author) , Perrin, C. (Author) , Timar David, M. (Author) , Dohollou, N. (Author) , Teixeira, L. (Author) , Brocard, F. (Author) , Arnaud, A. (Author) , Delaloge, S. (Author) , Spano, J. -P. (Author) , Mansi, L. (Author) , Damian, F. (Author) , Pedrini, J. (Author) , Aleixo, S. (Author) , Hegg, R. (Author) , Junior, R. (Author) , Schmidt, M. (Author) , Wenzel, C. (Author) , Grischke, E. -M. (Author) , Schneeweiss, A. (Author) , Just, M. (Author) , Harbeck, N. (Author) , Schumacher, C. (Author) , Peters, U. (Author) , Fischer, D. (Author) , Forstbauer, H. (Author) , Liersch, R. (Author) , Warner, E. (Author) , Bouganim, N. (Author) , Doyle, C. (Author) , Price Hiller, J. (Author) , Vandenberg, T. (Author) , Pavic, M. (Author) , Robinson, A. (Author) , Roldan Urgoiti, G. (Author) , Califaretti, N. (Author) , Alacacioglu, A. (Author) , Gumus, M. (Author) , Yalcin, B. (Author) , Cicin, I. (Author) , Kose, F. (Author) , Uygun, K. (Author) , Kaplan, M. (Author) , Cubukcu, E. (Author) , Harries, M. (Author) , Miles, D. (Author) , Doval, D. (Author) , Gupta, S. (Author) , Mohapatra, P. (Author) , Chatterjee, S. (Author) , Ghadyalpatil, N. (Author) , Singhal, M. (Author) , Nag, S. (Author) , Agarwal, A. (Author) , Wolf, I. (Author) , Gal Yam, E. (Author) , Yerushalmi, R. (Author) , Peretz, T. (Author) , Fried, G. (Author) , Ben Baruch, N. (Author) , Katz, D. (Author) , Hamilton, E. (Author) , Kayali, F. (Author) , Brufsky, A. (Author) , Telli, M. (Author) , Wright, G. (Author) , Oyola, R. (Author) , Rakowski, T. (Author) , Graff, S. (Author) , Tjulandin, S. (Author) , Aparicio, A. (Author) , Ruiz Borrego, M. (Author) , Merino, L. (Author) , Guerra Martinez, J. (Author) , Lopez, E. (Author) , Yamashita, T. (Author) , Ohtani, S. (Author) , Inoue, K. (Author) , Ito, Y. (Author) , Niikura, N. (Author) , Nakayama, T. (Author) , Sagara, Y. (Author) , Yanagita, Y. (Author) , Kamada, Y. (Author) , Kaneko, K. (Author) , Nervo, A. (Author) , Eniu, A. (Author) , Schenker, M. (Author) , Priester, P. (Author) , Melichar, B. (Author) , Zimovjanova, M. (Author) , Sormova, P. (Author) , Sufliarsky, J. (Author) , Kakalejcik, M. (Author) , Belbaraka, R. (Author) , Errihani, H. (Author) , Le Than, D. (Author) , Pham, D. (Author) , Aravantinos, G. (Author) , Papadimitriou, C. (Author) , Koumakis, G. (Author) , Papandreou, C. (Author) , Podolski, P. (Author) , Tabane, K. (Author) ,
Call Number: Loading…
Located: Loading…
Article (Journal) Online Resource -
2
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable ap... by Miles, David W. (Author) , Ciruelos, E. (Author) , Schneeweiss, Andreas (Author) , Puglisi, F. (Author) , Peretz-Yablonski, T. (Author) , Campone, M. (Author) , Bondarenko, I. (Author) , Nowecki, Z. (Author) , Errihani, H. (Author) , Paluch-Shimon, S. (Author) , Wardley, A. (Author) , Merot, J. -L. (Author) , Trask, P. (Author) ,
Call Number: Loading…
Located: Loading…
Article (Journal) Online Resource -
3
Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results from A... by Pivot, Xavier (Author) , Schneeweiss, Andreas (Author) , Verma, Shailendra (Author) , Thomssen, Christoph (Author) , Passos-Coelho, José Luis (Author) , Benedetti, Giovanni (Author) , Ciruelos, Eva (Author) , von Moos, Roger (Author) , Chang, Hong-Tai (Author) , Duenne, Anja-Alexandra (Author) , Miles, David W. (Author) ,
Call Number: Loading…
Located: Loading…
Article (Journal) Online Resource -
4
Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic brea... by Miles, David W. (Author) , Chan, Arlene (Author) , Dirix, Luc Y. (Author) , Cortés, Javier (Author) , Pivot, Xavier (Author) , Tomczak, Piotr (Author) , Delozier, Thierry (Author) , Sohn, Joo Hyuk (Author) , Provencher, Louise (Author) , Puglisi, Fabio (Author) , Harbeck, Nadia (Author) , Steger, Guenther G. (Author) , Schneeweiss, Andreas (Author) , Wardley, Andrew M. (Author) , Chlistalla, Andreas (Author) , Romieu, Gilles (Author) ,
Call Number: Loading…
Located: Loading…
Article (Journal) Online Resource
Search Tools:
Related Subjects
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized
Bevacizumab
Breast Neoplasms
Docetaxel
Female
Humans
Middle Aged
Neoplasm Metastasis
Neoplasm Recurrence, Local
Taxoids
paclitaxel
Angiogenesis Inhibitors
Antibodies, Monoclonal
Antineoplastic Agents
Antineoplastic Combined Chemotherapy Protocols
Disease-Free Survival
Drug Administration Schedule
Drug Therapy, Combination
ErbB Receptors
HER2 positive
PD-L1
Placebos
advanced breast cancer
atezolizumab
hormone receptor
immune checkpoint inhibitor
metastatic breast cancer